Ac Thérapeutiques et IS Flashcards

1
Q

Omalizumab

A

Anti-IgE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Éculizumab

A

Anti-C5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Canakinumab

A

Anti-IL-1B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Ustékinumab

A

Anti-IL-12, 23 par reconnaissance de leur portion p40 commune

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Palavizumab

A

Ac monoclonal neutralisant vs protéine F du VRS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Bévacizumab

A

IgG1 entière anti-VEGF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Ranibizumab

A

Fragment Fab anti-VEGF utilisé dans la DMLA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Basiliximab

A

IgG1 anti-chaîne alpha de l’IL-2R (IS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Daclizumab

A

IgG1 anti-chaine alpha de l’IL-2R (CD25)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tocilizumab

A

IgG1 anti-chaine alpha de l’Il-6R (polyarthrite rhumatoïde)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cétuximab

A

IgG1 anti-EGF-R (cytotoxicité)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Panitumumab

A

IgG2 anti-EGF-R

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Trastuzumab

A

IgG1 anti-R-HER2 (cytotoxicité)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Abciximab

A

Fragment Fab d’IgG1 anti-gpIIbIIIa (intégrine plaquettaire)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Éfalizumab

A

IgG1 anti-LFA-1 (trafic transendothélial lT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Natalizumab

A

IgG4 anti-VLA-4 (trafic lymphocytaire) (SEP)

17
Q

Alefacept

A

Protéine de fusion ectodomaine de LFA-3 et Fc d’une IgG1, liaison au CD2 (psoriasis)

18
Q

Abatacept

Bélatacept

A

Protéine de fusion entre ectodomaine CTLA-4 et Fc d’une IgG1 (IS, polyarthrite rhumatoïde, transplantation)

19
Q

Ipilimumab

A

IgG1 anti-CTLA4 (immunoactivation)

20
Q

Bélimumab

A

IgG1 anti-BAFF (lupus ES car blocage réponse humorale)

21
Q

Muromonab

A

IgG2a anti-chaine epsilon du CD3

22
Q

Alemtuzumab

A

IgG1 anti-CD52 (IS)

23
Q

Rituximab

Ofatumumab

A

IgG1 anti-CD20

24
Q

Infliximab
Adalimumab
Golimumab

A

IgG1 anti-TNFalpha soluble et membranaire

25
Q

Étarnecept

A

Protéine de fusion ectodomaine du TNF-RII et Fc d’une IgG1 (anti-TNFalpha soluble)

26
Q

Certolizumab pégol

A

Fragment Fab d’IgG1 anti-TNFalpha couplé à PEG

27
Q

Raxibacumab

A

IgG1 monoclonale antitoxine du bacille du charbon

28
Q

Anakinra

A

Antagoniste du R de l’IL-1

29
Q

Secukinumab

Ixekizumab

A

Ac anti-IL-17A

30
Q

Brodalumab

A

Ac anti IL-17RA

31
Q

Leflunomide

A

Inhibiteur de la DHODH, nécessaire à la synthèse de novo des pyrimidines (IS)

32
Q

Azathioprine

A

Inhibiteur analogue des bases puriques

33
Q

Mycophénolate Mofétyl

A

Inhibiteur de l’IMPDH, enzyme de la synthèse de novo des purines (IS)

34
Q

Méthotrexate

A

Antifolique inhibant la synthèse de DHFR qui régule la synthèse d’ADN (IS)

35
Q

Cyclophosphamide

A

Alkylant se fixant sur l’ADN par son radical alcoyl et bloquant le cycle cellulaire en G2 (IS)